Ispectamab debotansine

N/A

Report date: 2025/07/03 20:00:09

Base Information

Drug NameIspectamab debotansine
Drug Alias NameCC-99712BMS-986352SP-8919
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > DBCO linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Maytansine derivative payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelgene Corp
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A